RUTHERFORD, N.J., May 7, 2026
Glucotrack, Inc. announced the submission of an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study evaluating the company’s novel fully implantable Continuous Blood Glucose Monitoring (CBGM) technology for people living with diabetes. The IDE submission represents a major regulatory milestone as Glucotrack advances development of its long-term implantable glucose monitoring platform designed to provide continuous, real-time blood glucose measurements without requiring external wearable sensors or frequent sensor replacement. The company stated that the clinical study is expected to begin following FDA review and clearance of the IDE application.
Implantable CBGM Platform Designed for Long-Term Diabetes Monitoring
Glucotrack’s investigational CBGM system is being developed as a fully implantable continuous blood glucose monitoring technology capable of measuring blood glucose levels directly for up to three years with minimal calibration requirements. Unlike currently available wearable continuous glucose monitoring systems that require external patches, adhesive sensors, or regular sensor replacement, Glucotrack’s platform is designed to function entirely beneath the skin, eliminating the need for visible wearable components. The company believes this approach could significantly improve convenience, patient comfort, and long-term adherence for individuals managing diabetes through continuous glucose monitoring.
According to Glucotrack, the implantable device is intended to provide real-time blood-based glucose measurements while allowing users to carry out normal daily activities including work, exercise, sleep, and social activities without interruptions associated with external glucose monitoring devices. The company stated that several years of engineering development, preclinical testing, and iterative product refinement supported the IDE submission and established the technical foundation necessary to transition the technology into U.S. clinical evaluation.
IDE Submission Marks Important Regulatory Milestone
Advertisement
The FDA’s IDE pathway allows investigational medical devices to be evaluated in clinical studies to collect safety and effectiveness data before seeking commercial approval. Glucotrack stated that the submission reflects the company’s progress in advancing its implantable glucose monitoring technology toward human clinical testing and future regulatory development. The planned U.S. clinical study will evaluate the safety, performance, and usability of the CBGM platform as part of the company’s broader strategy to commercialize a long-term implantable glucose monitoring solution.
Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack, described the IDE filing as a significant advancement for the company’s diabetes technology program. He emphasized that the implantable system is designed to offer a discreet and comfortable glucose monitoring solution that reduces the burden associated with current wearable monitoring systems, including frequent sensor replacement and supply management. The company also stated that the upcoming clinical study will generate important data needed to support future regulatory submissions and demonstrate the potential advantages of fully implantable continuous glucose monitoring.
Growing Demand for Next-Generation Diabetes Monitoring Technologies
The continuous glucose monitoring market has expanded rapidly in recent years as diabetes management increasingly shifts toward real-time monitoring technologies capable of improving glycemic control and reducing complications associated with diabetes. However, many currently marketed CGM systems still rely on external wearable devices that require regular replacement and visible attachment to the body. Industry developers are increasingly exploring implantable and minimally invasive alternatives designed to improve long-term patient convenience and monitoring consistency.
Glucotrack’s investigational system enters a competitive diabetes technology landscape focused on improving accuracy, durability, patient comfort, and ease of use. The company believes its fully implantable blood-based monitoring platform may provide differentiated advantages by eliminating wearable components while maintaining continuous monitoring functionality. As regulatory review progresses, the upcoming clinical study is expected to provide important insight into the technology’s long-term clinical performance and potential role within the evolving diabetes device market.
Source: Glucotrack press release
